. Author manuscript; available in PMC: 2014 May 13.

Published in final edited form as: Prostaglandins Leukot Essent Fatty Acids. 2009 Jun 12;81(0):213–221. doi: 10.1016/j.plefa.2009.05.015

Table 5.

Omega-3 Fatty Acids in Clinical Trials For AD Treatment or Prevention.

Clinical Trials-completed	Reference
240 mg/ day DHA + AA (3 mos) improved memory and attention in amnestic MCI (n=12) (but not AD (N=8))	Kotani et al., 2006 (64)
4 g fish oil (1.7 g DHA for 6 months, n=174) ; no sig. effect for MMSE<27, but improved delayed recall, attention; MMSE >27 stabilized with w-3 (n=32)	Freund-Levi et al. 2006 (65)
Memo trial, normal or MMSE >21 (n=302, 65+ yrs, 1800 vs 400 mg EPA+DHA vs placebo for 26 wks)- increases in attention, especially in E4+ and men, but no change in cognition	Van de Rest et al., 2008 (104)
6 months 1.8 g/day total n-3 g showed improvement in ADAS-cog compared to olive oil with MCI (p=0.03), No effect in AD; NCT00628017	Chiu et al., 2008 (66)
OHSU pilot, MMSE 15-26 (n=39, Fish oil (750mg DHA, 1050 EPA +/- 600mg alpha lipoate vs placebo)- FO+ lipoate stabilized MMSE, ADLs (p=0.02), NCT00090402	Shinto et al., 2008 (67)

Abbreviations: activities of daily living (ADLs); arachidonic acid (AA); fish oil (FO); mild cognitive impairment (MCI); Oregon Health State University (OHSU).